Table 3.
Predicted 10‐year NNT with an anti‐PCSK9 antibody (with a predicted 60% LDL‐C reduction from baseline) to prevent 1 CVE for various absolute 10‐year risk of major CVEs and various baseline LDL‐C levels
| Absolute 10‐year risk of a major CVEa | Baseline LDL‐C levels, mg/dL (mmol/L) | Predicted LDL‐C reductions achieved with anti‐PCSK9 antibody treatment, mg/dL (mmol/L) | Predicted LDL‐C levels following anti‐PCSK9 antibody treatment, mg/dL (mmol/L) | Predicted 10‐year absolute risk of a major CVE with anti‐PCSK9 antibody treatmentb | 10‐year NNT to prevent 1 CVEc |
|---|---|---|---|---|---|
| 60% | 200 (5.2) | 120 (3.1) | 80 (2.1) | 28% | 4 |
| 160 (4.1) | 96 (2.5) | 64 (1.7) | 32% | 4 | |
| 120 (3.1) | 72 (1.7) | 48 (1.2) | 38% | 5 | |
| 80 (2.1) | 48 (1.2) | 32 (0.83) | 44% | 6 | |
| 30% | 200 (5.2) | 120 (3.1) | 80 (2.1) | 14% | 6 |
| 160 (4.1) | 96 (2.5) | 64 (1.7) | 16% | 7 | |
| 120 (3.1) | 72 (1.7) | 48 (1.2) | 19% | 9 | |
| 80 (2.1) | 48 (1.2) | 32 (0.83) | 22% | 13 | |
| 15% | 200 (5.2) | 120 (3.1) | 80 (2.1) | 7% | 13 |
| 160 (4.1) | 96 (2.5) | 64 (1.7) | 8% | 15 | |
| 120 (3.1) | 72 (1.7) | 48 (1.2) | 9% | 18 | |
| 80 (2.1) | 48 (1.2) | 32 (0.83) | 11% | 26 |
CTT, Cholesterol Treatment Trialists; CVE, cardiovascular event; LDL‐C, low‐density lipoprotein‐cholesterol; NNT, number needed to treat; PCSK9, proprotein convertase subtilisin/kexin type 9. aPatients may or may not be receiving LLT. bUsing data from the CTT meta‐analysis.5 cNNT for 10 years to prevent one CVE=100/([1−0.78n]×10‐year CVE risk in %), where n=LDL‐C reduction in mmol/L and 0.78 represents the decrease in CVD risk for each 1 mmol/L reduction in LDL‐C.5, 19